ArticleHealth science reports2025
Situation Analysis of Immune Response Status One Year After the Nationwide COVID-19 Vaccination in Cameroon: Role of Obesity and SARS-CoV-2 Infection.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Vaccines have been developed to control the COVID-19 pandemic, but vaccine coverage is low in sub-Saharan Africa. This study aimed at analysing the anti-SARS-CoV-2 immune response among vaccinated individuals. Methods: Between January and September 2022, a multicentre study took place in Douala, Cameroon. Blood samples were used for determining serum levels of anti-SARS-CoV-2 IgG and IgM antibodies, IL-6, IFN-γ, and CD4 + , while nasopharyngeal samples were used for molecular confirmation of SARS-CoV-2 infection. Each participant was administered an ad hoc questionnaire to document demographic, clinical, paraclinical, and anthropometric information. Results: The adjusted seroprevalence of IgM and IgG were 28% and 100%, respectively. Serum IgM levels were higher in those with current infection (235.73 ± 109.42 IU/mL) compared to those with past infection (105.18 ± 16.09 IU/mL), subpatent infection (27.86 ± 9.68 IU/mL), and no infection (15.17 ± 1.83 IU/mL). The levels of IgM were the highest in those vaccinated with Oxford AstraZeneca (73.75 ± 32.48 IU/mL) or Pfizer BioNTech (74.95 ± 26.92 IU/mL) compared to those vaccinated with Sinopharm (37.69 ± 15.55 IU/mL) or Janssen (22.89 ± 4.95 IU/mL). The immune response was significantly modulated by gender, patient's age, presence of any comorbidity, and obesity. In Pfizer BioNTech-vaccinated, the levels of IgG were reduced in obese participants. Conclusion: This study outlined a significant variation of immune response by type of vaccine, with the modulating effect of factors such as infection, demographical characteristics, and obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.